The oncology/cancer drugs market is driven by the growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, continuous patent expiry of key cancer drugs and the rising impact of biosimilars.
Oncology is in the front line of research and clinical trials.
Innovation is in our DNA and we want to be part of your journey and advance your studies.
First Generation Antibodies- Humanised Inhibitors
Second Generation Antibodies- Checkpoint Inhibitors
- Certificates of Analysis (CofAs)
- Batch Release Certificates (BRCs),
- Statements of Authenticity (SofAs),
Talk to our experts for all your requirements, firstname.lastname@example.org